Portugal Colocation Data Center Portfolio Analysis Report: Start Campus, Portugal Telecom (Altice) and Equinix Rank Among the Leading Data Center Operators by Capacity
Motus GI Announces Positive Clinical Data for Pure-Vu EVS in Three Poster Presentations at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting
Howard Energy Partners Receives Five-Star ESG Rating by GRESB, a Global Industry Benchmark in Sustainability
COVID-19 Impacts on Anheuser-Busch InBev - ResearchAndMarkets.com
Neurocrine Biosciences Presents Real-World Parkinson's Disease Patient Characteristics From ONGENTYS (Opicapone) Open-Label Study at ANA2022
United Kingdom Personal Insurance Claims Industry Report 2022 With Focus on Motor, Home, Travel, and Pet Insurance Markets - ResearchAndMarkets.com
New Medifast Survey Identifies Factors Associated With Successful Long-Term Weight Loss
AstroNova Expands Market Opportunity With Launch of Breakthrough Entry-Level QuickLabel E100 Color Label Printer
It's a Wipe-Out for Tricida (TCDA) Stock
Express News | Hedong Technology: plan to buy back shares from 20 million yuan to 40 million yuan
Global Patient Access/Front-end RCM Solutions Markets Report 2022-2027 - High Growth Potential in Emerging Healthcare IT Markets
Grovara Food Week Brings Top Better-for-You Brands, CPG Experts to Dubai to Jumpstart Seamless Global Wholesale Across Region
Brim Financial Ranked Best-in-Class on Product Capabilities in Credit-Cards-as-a-Service by Aite-Novarica Group
AV-Comparatives Pubblica Gli Ultimi Test Di Sicurezza IT Sui Software Antivirus per Imprese E Consumatori
Shareholders Have Faith in Loss-making Arrowhead Pharmaceuticals (NASDAQ:ARWR) as Stock Climbs 4.3% in Past Week, Taking Five-year Gain to 815%
FLOURISH VENTURES LAUNCHES AFRICA-FOCUSED PRE-SEED INVESTMENT PLATFORM MADICA
Invivoscribe Files SPMA With the FDA for Use of the LeukoStrat CDx FLT3 Mutation Assay to Select Patients With Newly Diagnosed FLT3-ITD Positive AML
11 Industrials Stocks Moving In Monday's Pre-Market Session
Shu Taishen (300204.SZ): STSA-1002 new drug clinical trial application accepted by FDA in the United States
Zhitong Financial APP, Shu Taishen (300204.SZ) notice, the company received the U. S. Food and Drug Administration (FDA) notice to accept STSA-1002 hypodermic injection on ANCA-associated vasculitis indications of new drug clinical trial application. It is reported that STSA-1002 is a recombinant anti-human C5aIgG1 monoclonal antibody targeting C5a, which specifically binds to the anaphylactotoxin C5a, which makes C5a lose its ability to bind to the receptor and block C5a-induced biological functions, such as neutrophil chemotaxis, degranulation and oxygen respiration burst.
UBS Says USD-JPY Not Yet at A Turning Point